KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,391,897 | -53.8% | 994,212 | 0.0% | 0.00% | – |
| Q2 2023 | $3,012,462 | -53.0% | 994,212 | -3.0% | 0.00% | – |
| Q1 2023 | $6,404,287 | +3.1% | 1,024,686 | +0.7% | 0.00% | – |
| Q4 2022 | $6,209,434 | -48.6% | 1,017,940 | +0.7% | 0.00% | – |
| Q3 2022 | $12,085,000 | -3.8% | 1,011,347 | +1.5% | 0.00% | – |
| Q2 2022 | $12,561,000 | -23.4% | 996,077 | -31.6% | 0.00% | – |
| Q1 2022 | $16,391,000 | -51.9% | 1,455,634 | -24.3% | 0.00% | -100.0% |
| Q4 2021 | $34,066,000 | -20.5% | 1,922,423 | +3.3% | 0.00% | 0.0% |
| Q3 2021 | $42,855,000 | +54.8% | 1,861,608 | +56.6% | 0.00% | 0.0% |
| Q2 2021 | $27,676,000 | -32.0% | 1,188,830 | -9.0% | 0.00% | 0.0% |
| Q1 2021 | $40,692,000 | +20.1% | 1,305,921 | +53.3% | 0.00% | 0.0% |
| Q4 2020 | $33,885,000 | – | 851,838 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |